Search for: "More v. Johnson" Results 2821 - 2840 of 5,443
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 May 2022, 5:01 am by Ben Johnson
Less than one year after Olmstead, the Court granted certiorari in Maryland Casualty v. [read post]
1 Feb 2010, 7:25 am by Erin Miller
  In his opinion in a more recent case involving the alleged educational benefits of diversity, Parents Involved in Community Schools v. [read post]
27 Nov 2015, 6:07 am
 You can read more about the facts in the case and the Supreme Court's decision in the news story you can find here.As noted above, the Supreme Court granted “the County’s and Lindquist’s petitions for review”. [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent… [read post]
16 Mar 2010, 7:05 am by Anna Christensen
Looking back at the Court’s March 2 ruling in Johnson v. [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs)… [read post]
29 Jul 2009, 3:47 am
  They’re arranged alphabetically, and include links to the opinions, as well as to other posts I’ve written discussing them in more detail. [read post]
15 Nov 2017, 11:28 am by vera
An incorrect claim about the inter partes review (IPR) and other procedures like IPR at the Patent Trial and Appeal Board (PTAB) has been circulating, and was recently repeated in written comments at a congressional hearing by Philip Johnson, former head of intellectual property at Johnson & Johnson. [read post]